According to a new market report published by Transparency Market Research “Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020”, the global anxiety disorders and depression treatment market was valued at USD 22.5 billion in 2013 and is expected to reach USD 18.2 billion in 2020, at a CAGR of (1.25%) from 2014 to 2020.
Anxiety is a biological reaction to stress, trauma and fear, which can be experienced by anyone in their lifetime, whereas depression is a mental state of low mood and aversion to daily activities that can affect an individual’s feelings, thoughts, sense of well-being and behavior. Depression affects 10% to 15% men and about 10% to 25% women. According to the World Health Organization (WHO), to date, over 350 million people have been affected by depression globally. The Anxiety and Depression Association of America revealed that at present approximately 40 million people in the U.S. are suffering from anxiety disorder and treating these patients costs around USD 42 billion each year. Thus, high prevalence of anxiety disorders and depression helped the market to transform itself into a billion dollar industry. However, the current scenario indicates that the overall anxiety disorders and depression treatment market would decline due to patent expiry of major antidepressants, weak pipeline of novel drugs and increasing number of generic drug variants.
Browse the full Anxiety Disorders and Depression Treatment Market Report at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html
The anxiety disorders and depression treatment market has been segmented based on the drug classes commonly used for the treatment of various types of anxiety disorders and depression such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs),...